The Orphan Regulation has stimulated the development of new treatments for patients living with previously untreatable rare diseases. Since the EU Orphan Regulation was adopted in 2000, the number of orphan medicines went from only 8 products to more than 160 today.

For every case where a new treatment has been developed there are however many more rare diseases that still need treatment options.

So much more needs to be done for the 1 in 17 Europeans living with a rare disease.

How can we ensure access to new treatments today, medical innovation for tomorrow and sustainable healthcare systems in a globally competitive Europe?

Featured speakers:
​Simone Boselli, Public Affairs Director, EURORDIS
Tidde Goldhoorn, Medicines: policy, authorization and monitoring, Health and Food Safety (DG SANTE), European Commission
Adam Hutchings, Managing Director, Dolon
Ulf Staginnus, Senior Vice President, Head Of Global Market Access And Pricing, Ipsen

Register here to join the conversation on 30 October!